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Vaginal probiotics have an important role in preventing the colonization of the vagina by pathogens.*is study aimed to investigate
di+erent formulations with Pediococcus pentosaceus SB&$ (lyophilized powder and tablets with and without retarding polymer)
in order to verify its stability and antilisterial activity a,er manufacture and during storage. *e bacteriocinogenic activity of P.
pentosaceus SB&$ against Listeria monocytogenes was evaluated in simulated vaginal -uid. Suspension of Pediococcus pentosaceus
SB&$ reduced the pathogen only a,er ! h and the lyophilized bacteria a,er !) h of contact, and, in the tablets, P. pentosaceus SB&$
lost the antimicrobial activity. *e pH of simulated vaginal -uid decreased for all the tested conditions. As lyophilized powder
demonstrated better results concerning antimicrobial activity, this formulation was selected to evaluate the antilisterial activity
during the #!months of storage. During storage at room temperature, lyophilized bacteria totally inhibited the pathogen only until
onemonth of storage.At )!C,P. pentosaceus SB&$ showed antimicrobial activity during all the time of storage investigated.*erefore,
the better formulation of P. pentosaceus SB&$ is the lyophilized powder stored at )!C, which may be administered intravaginally as
a washing solution.
1. Introduction
*e dominant microorganisms in vaginal microbiota are
lactobacilli, with a concentration of #"7 to #"8 CFU/mL
of vaginal -uid in healthy premenopausal women [#, !].
However, other lactic acid bacteria (LAB) genera have been
found in the vaginal tract, such as Pediococcus spp., Weisella
spp., Streptococcus spp., and Leuconostoc spp. [$].Moreover, it
is acknowledged that the composition of the microbiota can
vary from day to day, even in women without an indication
of infections [)].
*e normal vaginal pH of a healthy woman is acidic
()–).(), with variations from %.% (+/!".$) to ).! (+/!".!)
between day ! and day #) of the menstrual cycle [(], although
vaginal pH can rise with the diminishing of LAB existing
in the vaginal microbiota, since glucose is not converted to
lactic acid. High pH values promote growth of pathogenic
organisms, particularly, colonization by enteric bacteria [!].
*e microorganisms that are normally present in the
vaginal environment play a major role in preventing illnesses
of the host, including bacterial vaginosis (BV), urinary tract
infections (UTI), yeast vaginitis, and sexually transmitted
diseases including human immunode.ciency virus (HIV)
[%]. *e vaginal LAB are also able to reduce the incidence
of ascending infections of the uterus and the subsequent
production of proin-ammatory molecules [']. During preg-
nancy, several genital microorganisms such as Escherichia
coli, Listeriamonocytogenes, and viridans streptococcimay be
involved in chorioamnionitis [&].
Antimicrobial treatment of urogenital infections is not
always e+ective, and problems remain due to bacterial and
yeast resistance. To minimize recurrent infections, as well as
side e+ects, it is important to develop and produce alternative
treatments or drugs [/].
Due to the bene.cial characteristics of LAB, there has
been a growing interest in the potential use of LAB as
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probiotics for maintaining normal urogenital health [#"].*e
World Health Organization and the Food and Agriculture
Organization of theUnitedNations have de.ned probiotics as
“livemicroorganisms, which, when administered in adequate
amounts, confer a health bene.t on the host” [##].
A probiotic may act indirectly through treating and
preventing recurrent BV or directly by secreting substances
(e.g., hydrogen peroxide, bacteriocins, and lactic acid) that
inhibit pathogens [#!].
Vaginal dosage forms available include creams, gels,
tablets, capsules, pessaries, foams, ointments, .lms, tampons,
rings, and douches. While the majority of vaginal drugs so
far have been in the form of gels, there is a growing interest
in alternative dosage forms such as rings, tablets, and .lms.
*e majority of issues with product development and scaleup
are similar to other pharmaceutical products, although there
are some unique challenges because of the site of delivery,
prophylactic nature of product application, and diversity in
sex and hygiene practices across the developing world [#$].
*e purpose of this study was to develop a vaginal
formulation containing viable cells of a LAB isolate which
can be used by women to prevent vaginal colonization of
microorganisms (e.g., L.monocytogenes) thatmay be harmful
to the fetus/neonate. In this study the probiotic properties
(survival and antagonistic activity) of formulations were
evaluated a,er manufacture and during long-term storage of
the product at di+erent temperatures.
2. Material and Methods
#.!. Microorganisms and Culture Conditions. Pediococcus
pentosaceus SB&$ (Escola Superior de Biotecnologia Culture
Collection) was selected because previous studies demon-
strated that this strain is able to inhibit the growth of clinical
isolates of L. monocytogenes (serotype #/!a, #/!b and )b) by
production of a bacteriocin [#), #(]. *is strain has been
shown to survive in simulated vaginal -uid at normal vaginal
pH (pH of ).!), and P. pentosaceus SB&$ does not produce
virulence factors such as gelatinase, lipase and DNase, and
hemolytic activity, nor does it possess virulence genes (genes
esp, agg, gelE, efaAfm, efaAfs, cylA, cylB, and cylM) [#(].
Pediococcus pentosaceus SB&$ was grown on de Man,
Rogosa and Sharpe (MRS) agar (Lab M, Bury, United King-
dom) and was subcultured twice in MRS broth (Lab M) at
$'!C for !) h before use in all tests.
*e pathogenic bacteria, L. monocytogenes !"/! )b (iso-
lated from blood; Escola Superior de Biotecnologia Culture
Collection), was grown on Tryptone Soya agar with Yeast
Extract ".%% (w/v) (TSA-YE, Lab M) and subcultured in
Tryptone Soya broth with Yeast Extract (TSB-YE, Lab M) at
$'!C for !) h.
All strains were stored at !&"!C in the presence of $"%
(v/v) glycerol (Panreac, Barcelona, Spain).
#.#. Preparation of Freeze-Dried Cells. A,er growth of P.
pentosaceus SB&$ in MRS broth, cultures were harvested
by centrifugation at &&''"g for #"min at )!C and washed
twice in sterile Ringer’s solution (Oxoid, Hampshire, United
Kingdom). *e harvested cells were then suspended to the
original volume in ##% (w/v) of skim milk (Oxoid). *e
cultures were frozen at !&"!C for !) h and subsequently
freeze-dried (Martin Christ, Osteradam Harz, Germany) for
!-$ days.
#.(. Preparation of Vaginal Tablets. *e formulations of vagi-
nal tablets constituted di+erent excipients: $.$% talc (Aco-
farma, Barcelona, Spain), $."% magnesium stearate (J.M.V.
Pereira, Portugal), ".!% colloidal silicon dioxide (Acofarma),
'.(% hydroxypropyl methylcelluloses (HPMC, Acofarma)
as retarding polymer, and &%."% of lyophilized bacteria.
Simultaneously, tablets without the retarding polymer were
also prepared.
*e HPMC are known to show bioadhesive properties,
but they are also able to hydrate and gel very slowly due
to their high molecular weights and viscosities; for this
reason, the tablet dissolves over a longer time and provides
a prolonged release of the active ingredient embedded in the
polymeric matrix [#%]. *e powder contained an amount of
magnesium stearate as lubricant and talc as antiadherent [#'].
All compounds were mixed in a Turbula apparatus for
#(min. *en, tablets were prepared by direct compression
using a single-punch tablet press (Specac Ltd., Kent, United
Kingdom). A quantity of themixture (approximately %""mg)
was .lled into a die of ##mm diameter and under a pressure
of /.& kN, and tablets with a plane surface were formed.
*e possible adverse e+ects of pressing on bacterial
viability were investigated by comparing the viability of cells
in tablets with those in formulated powders.
#.". Release Study of Vaginal Tablets. *e determination
of the release of P. pentosaceus SB&$ from vaginal tablets
was done using simulated vaginal -uid (SVF). Simulated
vaginal -uid was prepared according to Owen and Katz
[#&]: $.( g/L NaCl (Panreac); #.) g/L KOH (Pronalab, Lisbon,
Portugal); ".! g/L Ca(OH)2 (Merck, Darmstadt, Germany);
"."! g/L bovine serum albumin (Sigma-Aldrich, Steinheim,
Germany); !." g/L lactic acid (Fluka, Steinheim, Germany);
#." g/L acetic acid (Panreac); ".! g/L glycerol; ".) g/L urea
(Sigma-Aldrich); (." g/L glucose (Pronalab). Once these
compounds were combined in solution, the mixture was
adjusted to a pH of ).!, (.(, and %.( using HCl (Pronalab) or
NaOH (Pronalab). *ese pH values were used to reproduce
the vaginal pH in normal conditions (pH ).!) and in the case
of infection (pH (.( and %.(). As control, Ringer’s solutionwas
used.
Tablets with and without retarding polymer were placed
in ten millilitres of each solution at $'!C, since the daily
production of vaginal -uid ranges between #.&/–##.""mL/day
[#&]. At appropriate time intervals, aliquots were withdrawn
for further enumeration of viable bacteria. Two independent
replicates of these assayswere performed.*e enumeration of
P. pentosaceus SB&$ was performed by serial #"-fold dilutions
in Ringer’s solution, and !" #L was spread-plated in duplicate
on MRS agar. Colony forming units per gram (CFU/g) was
determined a,er )& h of incubation at $'!C.
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#.'. Viability of Pediococcus pentosaceus SB&( in Tablets and
Lyophilized Powder. Freeze-dried powder and pharmaceu-
tical preparations (freeze-dried powder with excipients and
tablets) were stored in plastic containers at room temperature
and at )!C for #! months. At several time intervals (", #,
$, %, /, and #! months), the viability of P. pentosaceus SB&$
was determined by plate method using MRS agar medium
(described above). *e detection limit of the enumeration
technique was #.) log CFU/g.
#.). Evaluation of Antimicrobial Activity of Pediococcus pen-
tosaceus SB&( in Simulated Vaginal Fluid. Pediococcus pen-
tosaceus SB&$ produce a bacteriocin against L.monocytogenes
that is resistant to the components and pH of vaginal -uid
[#)].
*e bacterial suspension, lyophilized powder, and tablets
were used in these experiments to evaluate the antimicrobial
activity of P. pentosaceus SB&$ in SVF. To obtain the bacterial
suspension, the microorganism was subcultured twice (!) h
at $'!C) in #"mL MRS broth, using a #% v/v inoculum.
*en cultures were harvested by centrifugation at &&''"g for
#"min at )!C, washed twice in sterile Ringer’s solution, and
the pellet of bacteria was used. *e lyophilized powder and
tablets were prepared as described above.
Simulated vaginal -uid at pH of %.( was inoculated with
an overnight culture of L. monocytogenes !"/! )b suspended
inRinger’s solutionwith a.nal concentration of #"5CFU/mL.
*en, P. pentosaceus SB&$ (bacterial suspension, lyophilized
powder, or tablet) was added.
During !) h, aliquots were withdrawn for further enu-
meration (P. pentosaceus SB&$ and L. monocytogenes !"/! )b)
and for pH measurement.*e enumeration of P. pentosaceus
SB&$ was performed on MRS agar and the enumeration
of L. monocytogenes on PALCAM agar (Merck), a,er )& h
incubation at $'!C.
*e experimental conditions were (#) SVF inoculated
with P. pentosaceus SB&$ (bacterial suspension, lyophilized
powder, tablet with retarding polymer, and tablet without
retarding polymer) and L. monocytogenes !"/! )b, (!) SVF
with #mg/mLof trypsin (Sigma-Aldrich) and inoculatedwith
P. pentosaceus SB&$ and L. monocytogenes !"/! )b, ($) SVF
inoculated with a nonbacteriocinogenic LAB strain ESB%'
(Escola Superior de Biotecnologia Culture Collection) and
L. monocytogenes !"/! )b, ()) SVF inoculated with P. pen-
tosaceus SB&$, and (() SVF inoculated with L. monocytogenes
!"/! )b. Each trial was performed in duplicate.
A,er this experiment, the formulation of P. pentosaceus
SB&$ that demonstrated the better results of antilisterial
activity was selected; the formulation was then stored at
room temperature and )!C for #! months. At #, $, %, /,
and #! months, the evaluation of antimicrobial activity of P.
pentosaceus SB&$ was performed as previously described.
#.%. Statistical Analysis. An analysis of variance (ANOVA)
was carried out to assess (#) the e+ect of pH in the release
of P. pentosaceus SB&$ in tablets with and without retarding
polymer, (!) the e+ect of time and temperature of storage
on viability of P. pentosaceus SB&$ in tablets and lyophilized
powder, ($) the e+ect of di+erent forms of P. pentosaceus
SB&$ (bacterial suspension, lyophilized powder, and tablets)
for antilisterial activity and reduction of pH of SVF, and ())
the e+ect of storage on antilisterial activity and reduction of
pH of SVF. All calculations were carried out using the so,-
ware Kaleidagraph (version )."), Synergy So,ware, Reading,
USA).
3. Results
(.!. Enumeration of Pediococcus pentosaceus SB&( in Lyo-
philized Powder and Tablets. *e number of P. pentosaceus
SB&$ in lyophilized powder and in tablets (with and without
retarding polymer) was #"10 CFU/g.
(.#. Release Study of Vaginal Tablets. *e release of P.
pentosaceus SB&$ from tablets with and without retarding
polymer is shown in Figure #.
In tablets with retarding polymer, P. pentosaceus SB&$was
not completely released in all media tested. In SVF at pH ).!
a lower release was observed (approximately (." log CFU/g)
than the release in the other media (SVF at pH (.(, SVF at
pH %.( and Ringer’s solution) that was approximately &." log
CFU/g.
In tablets without retarding polymer, P. pentosaceus SB&$
was completely released a,er )& h in SVF at pH (.(, SVF at pH
%.(, and Ringer’s solution. *e release of bacteria was lower
in SVF at pH ).!, with values being approximately &." log
CFU/g.
*erefore, in both tablets (with and without retarding
polymer) the bacteria release characteristics were found to be
di+erent when comparing the release in SVF at pH ).! with
the other media ($ < 0.0001).
In either of the tablets, there was a large release of bacteria
in the early hours of contact.
(.(. Viability of Pediococcus pentosaceus SB&( in Tablets
and Lyophilized Powder. Figure ! shows the viability of P.
pentosaceus SB&$ in lyophilized powder and pharmaceutical
formulations (lyophilized powderwith excipients and tablets)
during storage at room temperature and )!C.
At room temperature, in conditions with retarding poly-
mer (Figure !(a)), the survival was similar during / months
of storage ($ = 0.09). However, a,er #! months of storage,
the tablets showed a greater decrease of viable cells (reduction
of /.( log CFU/g) than that of lyophilized powder and
lyophilized powder with excipients. In conditions without
retarding polymer (Figure !(b)), no signi.cant di+erences
were found between lyophilized powder, lyophilized powder
with excipients, and tablets ($ = 0.18) during storage.
At )!C, in both conditions (with and without retarding
polymer) a higher survival of P. pentosaceus SB&$ was
recorded during storage than at room temperature ($ <0.05).
(.". Evaluation of Antimicrobial Activity of Pediococcus
pentosaceus SB&( in Simulated Vaginal Fluid. Figure $ shows
the antimicrobial activity of P. pentosaceus SB&$ (in bacterial

































F01234 #: Release of Pediococcus pentosaceus SB&$ from (a) tablets with retarding polymer and (b) tablets without retarding polymer. *e
release of bacteria was tested in SVF at pH = ).! (%); pH = (.( (&); pH = %.( (!) and in Ringer’s solution ('). All points are means ± standard
deviations.




































F01234 !: Viability of Pediococcus pentosaceus SB&$ in preparations with (a) retarding polymer and (b) without retarding polymer during
storage.*e viability was examined in freeze-dried powder ('), freeze-dried powder with excipients (%), and tablets (&) at room temperature
(black lines) and at )!C (grey lines). All points are means ± standard deviations.
suspension, lyophilized powder, and tablets with and without
retarding polymer) against L. monocytogenes !"/! )b, in SVF
at pH = %.(.
*e bacterial suspension of P. pentosaceus SB&$ reduced
L. monocytogenes !"/! )b below the detection limit a,er only
! h. *e lyophilized bacteria inhibited Listeria population
mainly over & h of contact; however, total inhibition (up to the
limit of detection) was recorded a,er !) h.*e tablets did not
reduce L. monocytogenes !"/! )b during !) h of experiment
($ = 0.11) (Figure $(a)).
*e viable counts of P. pentosaceus SB&$were maintained
throughout the !) h in all conditions tested (data not shown).
All conditions tested, demonstrated the ability to decrease
the pH of SVF (Figure $(b)). However, the highest reduction
of pH was observed for bacterial suspension, followed by the
lyophilized cells. *e lowest reduction of pH was observed
when tablets formulations were used. No signi.cant di+er-
ence was achieved for tablets with and without retarding
polymer ($ = 0.94).
A,er obtaining these results, lyophilized bacteria were
selected to evaluate the antilisterial activity during storage at
room temperature and at )!C for #!months (Figure )).
*e lyophilized bacteria, when stored at room temper-
ature, totally reduced L. monocytogenes !"/! )b (up to the
limit of detection) until onemonth of storage. A,er $months,
a decrease in antimicrobial capability was observed. From $
to #! months of storage, there was a similar behaviour ($ >0.05), and the pathogen was reduced in the early hours of
contact with the LAB isolate, though there was an increase
of L. monocytogenes !"/! )b a,er !) h (Figure )(a)).
When storage was performed at )!C, the antimicrobial
activity of P. pentosaceus SB&$was maintained during storage
($ = 0.66), showing only a slight decrease in antimicrobial
potential a,er #!months (Figure )(d)).
As previously observed, lyophilized P. pentosaceus SB&$
were more stable at )!C than room temperature (Figures )(b)
and )(e)).
During storage of the lyophilized bacteria at room tem-
perature, the ability of P. pentosaceus SB&$ to reduce the pH
of SVF decreased over time ($ < 0.001) (Figure )(c)). In con-
trast, during storage at )!C the ability to reduce the pHof SVF
throughout the time of storage was observed. *is capacity
only decreased slightly with time ($ = 0.66; Figure )(f)).
4. Discussion
*e intravaginal route is normally used for the administration
of drugs such as antimicrobials, labour-inducing agents,
spermicidal agents, prostaglandins, and steroids [#/]. Accord-
ingly, the vaginal route can be used to prevent vaginal colo-
nization by pathogenic microorganisms in pregnant women,
and thereby is a method of protection of the fetus/neonate.
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F01234 $: Antimicrobial activity of Pediococcus pentosaceus SB&$ against Listeria monocytogenes !"/! )b in simulated vaginal -uid at pH =
%.(. (a) Counts of viable cells of Listeria monocytogenes !"/! )b and (b) pH of simulated vaginal -uid during !) h of contact, are represented.
*e tested conditions were SVF inoculated with bacterial suspension of P. pentosaceus SB&$ and L. monocytogenes !"/! )b ('); lyophilized of
P. pentosaceus SB&$ and L. monocytogenes !"/! )b (%); tablet of P. pentosaceus SB&$ with retarding polymer and L. monocytogenes !"/! )b
(&), tablet of P. pentosaceus SB&$ without retarding polymer and L. monocytogenes !"/! )b (!). Controls were: SVF with #mg/mL of trypsin
and inoculated with P. pentosaceus SB&$ and L. monocytogenes !"/! )b (( ( ( ), SVF inoculated with a non-bacteriocinogenic LAB strain ESB%'
and L. monocytogenes !"/! )b (– –), and SVF inoculated with P. pentosaceus SB&$ (—), SVF inoculated with L. monocytogenes !"/! )b (– ().
All points are means ± standard deviations.
Based on this principle, di+erent pharmaceutical formu-
lations with P. pentosaceus SB&$, a bacteriocin-producing
LAB [#)], were performed for subsequent vaginal adminis-
tration.
In this study freeze-dried cells of P. pentosaceus SB&$
were used, containing #"10 CFU/g, which remained a,er the
production of tablets, so tabletting had no adverse e+ect
on the viability of bacteria. Generally, the quantity used for
vaginal probiotics is between #"8 and #"10 CFU in the product
[#%, !"–!!].
*e normal vaginal pH in premenopausal women is
acidic; however, vaginal pH can be increased due to a deple-
tion of vaginal lactobacilli [!$], menstruation, unprotected
sexual intercourse with the deposition of semen [!)], and
vaginal medications. *erefore, we tested the release of P.
pentosaceus SB&$ in SVF at di+erent values of pH ().!, (.(, and
%.(). *e pH in-uenced the release of bacteria from tablets.
Tablets with retarding polymer as well as tablets without
retarding polymer released fewer cells of P. pentosaceus SB&$
at pH ).!.
*e presence of retarding polymer a+ected the total
numbers of bacteria released. *e polymer used (HPMC)
retained P. pentosaceus SB&$ inside the tablets, releasing
a maximum of #"8 CFU/g. However, this release occurred
in the early hours of contact with SVF, such as in tablets
without the retarding polymer. Fazeli et al. [!(] performed
an assay with tablets with HPMC and concluded that a high
initial bacterial load release occurs during the .rst #(min
in deionized sterile water; however, the tablets showed a
continuous bacterial release during (.'( h.
*e tablets and lyophilized powder were stored during
#! months in order to determine their stability. *ere was
an e+ect of temperature on viability of cells during storage;
P. pentosaceus SB&$ showed a higher survival rate at )!C
than at room temperature. According to other studies, freeze-
dried bacteria are more stable at low temperatures than at
room temperature [#', !%]. It was reported thatmilk promotes
survival at low temperature by stabilizing the cell membrane
constituents and forming a protective coating on the cell wall
proteins (see review [!']).
At )!C the viability of P. pentosaceus SB&$wasmaintained
at a high level in all formulations tested for at least #!months.
Fazeli et al. [!(] also demonstrated that slow-release tablets
were stable at )!C during % months of storage. Maggi et al.
[#%] tested the viability of #" lactobacilli strains in freeze-dried
powder and tablets and have shown that the stability depends
on the bacterial strain and also on the polymer used as a
retarding compound. In their study, four strains of lactobacilli
maintained a high viability for #&months at )!C.
While observing an elevated survival of bacteria during
storage, it is important to con.rm that the antimicrobial char-
acteristics are alsomaintained. In previous studies, our group
characterized the bacteriocin produced by P. pentosaceus
SB&$ in MRS medium [#)] and tested the antimicrobial
activity of P. pentosaceus SB&$ a,er exposure to SVF at pH
).! a,er !) h [#(]. However, it is relevant to evaluate the
production and e+ectiveness of bacteriocin production by
the LAB a,er storage, in SVF, in case of vaginal colonization
by pathogens (elevated pH). *e pathogen selected to assess
these parameters was L. monocytogenes. *is bacterium
can be acquired via vertical transmission from mother to
fetus/neonate through the placenta or birth canal [!&, !/] and
can lead to preterm labour, chorioamnionitis, spontaneous
abortion, stillbirth, and neonatal infection [$"].
In experiments to determine the inhibitory activity of
stored cells of P. pentosaceus SB&$, SVF at pH of %.( was
used because it was demonstrated previously that clinical
strains of L. monocytogenes are inhibited by the normal
vaginal pH for )& h butmay proliferatewhen the pH increases
[$#].
*e bacterial suspension of P. pentosaceus SB&$ reduced
L. monocytogenes !"/! )b below the detection limit a,er only
% BioMed Research International


















































































F01234 ): Antimicrobial activity of lyophilized of Pediococcus pentosaceus SB&$ against Listeria monocytogenes !"/! )b in simulated vaginal
-uid at pH = %.( during storage at room temperature (black lines) and at )!C (grey lines). ((a) and (d)) Counts of viable cells of Listeria
monocytogenes !"/! )b; ((b) and (e)) counts of viable cells of Pediococcus pentosaceus SB&$; ((c) and (f)) pH of simulated vaginal -uid
overtime are represented. *ese parameters were evaluated at storage time of " ('), # (%), $ (&), % ("), / (5), and #! (!) months. All points
are means ± standard deviations.
! h (reduction of approximately )." log).*e pH of SVF was
decreased to normal vaginal pH ().!) in !) h.
*e lyophilized bacteria showed a total inhibition of the
pathogen a,er !) h of contact. *e pH of SVF decreased to
values of ).( in !) h.
*e tablets did not reduce counts of L. monocytogenes
!"/! )b, although the bacteria in the tablets were able to
decrease the pH to values of (.( in !) h.*ese results showed
that the activity of the bacteriocin SB&$ was a+ected by
the excipients used in production of tablets, probably by its
adsorption to the excipients. It has been reported that some
compounds commonly used as pharmaceutical excipients
and/or starter culture cryoprotectants can alter or completely
inhibit the activity of bacteriocins [$!]. *e reduction in
pH was rather less by cells in tablets than by lyophilized
cells; this also suggests that the tabletted cells are rather less
metabolically active than lyophilized cells.
In the controls used (SVF with #mg/mL of trypsin and
inoculated with P. pentosaceus SB&$ and L. monocytogenes
!"/! )b; SVF inoculated with a nonbacteriocinogenic LAB
strain ESB%' and L. monocytogenes !"/! )b), there was no
inhibition of pathogen, while there was a decrease of pH.*is
suggests that the antimicrobial activity observed in bacterial
suspension and lyophilized in SVF was due to the production
of bacteriocin SB&$.
*e studies performed on the production of bacteriocins
in the vaginal environment are very few. According to
the study by Tomás and Nader-Maćıas [$$], Lactobacillus
salivarius CRL #$!& was able to grow in SVF at ).!(, but that
bacteriocin production was minimal, only )"AU/mL.
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*e lyophilized powder demonstrated antimicrobial
activity; therefore, this formulation was selected to evaluate
the antilisterial activity during the #! months of storage. In
pharmaceutical products it is important to verify the stability
of the bioactive compounds and the maintenance of the
biological activity during long periods of storage.
When stored at room temperature, lyophilized cells
inhibited totally the pathogen (up to the limit of detection) up
to one month of storage. A,er this time, there was a decrease
in antimicrobial potential that may be caused by diminishing
numbers of viable cells of P. pentosaceus SB&$ during storage
at room temperature. *is decrease in the number of cells
could also have in-uenced the reduction of pH of SVF; the
production of acid is lower with storage time of P. pentosaceus
SB&$ cells.
When lyophilized cells were stored at )!C, P. pentosaceus
SB&$ maintained their viability, and consequently the anti-
listerial activity and the capacity to produce acid were
observed throughout the time of storage. *e bacteriocin
SB&$ remained active during at least #! months in spite of a
decrease that occurred in antimicrobial activity at the twel,h
month of storage.
Zárate and Nader-Macias [$!] evaluated the bacterio-
cinogenic activity of L. salivarius CRL #$!& a,er lyophiliza-
tion (with di+erent protective substances, such as lactose,
skim milk, ascorbic acid, and combinations of them) during
storage at (!C. It was demonstrated that bacteriocin synthesis
was not a+ected by the lyophilization, but a slight decrease of
activity was observed during storage in cells lyophilized with
lactose and completely abolished in cells lyophilized with
ascorbic acid.
Pingitore et al. [$)] tested the activity of a lyophilized
bacteriocin (salivaricin) during storage at !!(!C, )!C, and
!(!C for #& months. *e antimicrobial activity of salivaricin
was dependent mainly on temperature and also on the time
of storage and protectant used to lyophilize. *e stability of
salivaricin was higher at temperatures lower than !(!C and
decreased during the time of storage.
To our knowledge, this is the .rst study where the
bacteriocin production of lyophilized bacteria was tested
against L. monocytogenes under the conditions of vaginal
-uid and throughout #!months of storage.
*e assays for antimicrobial activity were performed
against L. monocytogenes; nevertheless bacteriocin SB&$ also
inhibits the growth of Enterococcus spp. [#)]; thus, the
lyophilized cells may also be used to prevent UTI caused by
this pathogen.
Pediococcus pentosaceus SB&$ showed the ability to reduce
the pH of SVF, which is relevant because in addition to
inhibiting those pathogens previously mentioned, this LAB
has the capability of preventing colonization by other vagi-
nal pathogens by reduction of vaginal pH acid; one study
reported the inhibition of group B Streptococcus in SVF at
pH ).! [$(]. Moreover, the maintenance of the acidic vaginal
pH will allow the proliferation of the vaginal Lactobacillus
spp. belonging to the normal microbiota of the vaginal
tract. Hemalatha et al. [$%] demonstrated that a probiotic
lactobacilli tablet was found to be better than a pH lowering
vaginal tablet in preventing BV in healthy subjects.
5. Conclusions
*e better formulation of P. pentosaceus SB&$ is the
lyophilized powder whichmay be administered vaginally as a
washing solution. Based on the tests carried out, the product
must be stored at )!C and can be used for a period of time
of / months. If storage is performed until this time, the
characteristics of cells are maintained, that is, the number of
viable cells, the production of an active bacteriocin, and the
ability to reduce vaginal pH.
Further assays need to be performed, including adhesion
to vaginal epithelial cells and clinical trials, to determine
the frequency of administration and the e+ectiveness of
in vivo of the lyophilized powder of P. pentosaceus SB&$.
Other formulations can be tested using lyophilized bacteria,
including tablets with suitable excipients, ovules, and gels.
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